Assessment of the risk of subclinical hypothyroidism in non-alcoholic fatty liver disease patients with different levels of cardiovascular risk

  • A.V. Potapenko
Keywords: subclinical hypothyreosis, non-alcoholic fatty liver disease, early thyroid status disorders, cardiovascular risk


To assess the risk of developing subclinical hypothyroidism (SH) in patients with non-alcoholic fatty liver disease (NAFLD) with a different risk of cardiovascular complications, and to identify the link between high risk of developing SH and major cardiovascular factors (CV). A one-stage clinical trial included 298 people with NAFLD with the presence of one or more CV risk factors (arterial hypertension, smoking, hypercholesterolemia) and various levels of CV risk factors on the SCORE scale. All patients were questioned on a standard questionnaire and HRQ, a thyroid status study was conducted. Patients were divided into three groups according to the level of total CV risk for SCORE: 33.9% had low / moderate CV risk, 41.9% - high and 24.2% - very high CV risk. The majority of the subjects were in the age groups 50–59 and 60–69 years. In the age group 40–49 years, 22.2% of patients had high CV risk, 28% of men aged 50-59 years had moderate CV risk, while 49.7% of older patients showed very high CV risk. According to the results of a survey on the HRQ questionnaire, a low risk of developing hypertension was found in 34.9%, a moderate risk in 48.9%, and a high risk was found in 16.1% of patients. Persons with a very high CV risk on the SCORE scale also have a high risk of developing the SH according to the HRQ questionnaire. Among patients with the presence of one or more of the above CV risk factors, early markers of thyroid status disorders should be identified and the risk of developing hypertension should be assessed. Such a tactic contributes to an adequate assessment of the risk of SH in patients with NAFLD and the development of methods for primary prevention.


1. Dreval, A. V. (2016) Endokrinologiya: rukovodstvo dlya vrachej. M. GEOTAR-Media. [in Russian].

2. Adrees, M., Gibney, J., El-Saeity, N., & Boran, G. (2009). Effects of 18 months of L-T4 replacement in women with subclinical hypothyroidism. Clin. Endocrinol., 71(2), 298–303. Doi: 10.1111/j.1365-2265.2008.03509.x [in Russian].

3. Blum, M. R., Collet, T. H. & Krebs, D. (2013). Subklinische Hypothyreose. Schweiz. Med. Forum, 13(39), 772–5.

4. Chung, G. E., Kim, D., Kim, W., Yim, J. Y., Park, M. J., Kim, Y. J. … & Lee H. S. (2012). Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. J. Hepatol., 57(1), 150–156.

5. Hollowell, J. G., Staehking, N. W., & Flanders, W. D. (2002). Serum TSH, N4, and thyroid antibodies in the United State population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab., 12, 839–847.

6. Collins, J. J. (2011-2016). Hypothyroid Risk Questionnaire™. Retrieved from

7. Liu, D., Jiang, F., Shan, Z., Wang, B., Wang, J., Lai, Y. … Teng, W. (2010). A cross-sectional survey of relationship between serum OOA level and blood pressure. J. Hum. Hypertens., 24(2), 134–138. DOI: 10.1038/jhh.2009.44

8. Monzani, F., Caraccio, N., Kozakowa, M., Dardano, A., Vittone, F., Virdis, A., ... & Ferrannini E. (2004). Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study. J Clin Endocrinol Metab. 89 (5), 2099–106. DOI: 10.1210/jc.2003-031669

9. Mǜller, B. (2010). “Subklinische” Hypo- und Hyperthyreose. Schweizerische Gesellschaft für Endokrinologie und Diabetologie. Retrieved from – 2011/SGED_Subklinische_Hypo_Hyperthyresose.pdf 2010–2011.

10. Razvi, S., Ingoe, L., Keeka, G., Oates, C., McMillan, C. & Weaver, J.U. (2007). The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J. Clin. Endocrinol. Metab., 92(5), 1715–1723. DOI: 10.1210/jc.2006-1869.

11. Razvi, S., Weaver, J. U., Butler, T. J. & Pearce, S. H. (2012). Levothy-roxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. Arch Intern Med, 172(10), 811–817. DOI: 10.1001/archinternmed.2012.1159

12. Rodondi, N., den Elzen, W. P., Bauer, D. C., Cappola, A. R., Razvi, S., Walsh, J. P. … Gussekloo, J. (2010). Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA, 304, 2998–3007. DOI: 10.1001/jama.2010.1361

13. Walsh, J. P., Bremner, A. P., Bulsara, M. K., O'Leary, P., Leedman, P. J., Feddema, P. & Michelangeli, V. (2006). Subclinical thyroid dysfunction and blood pressure: a community-based study. Clin. Endocrinol., 65(4), 486–491. DOI
How to Cite
Potapenko, A. (2017). Assessment of the risk of subclinical hypothyroidism in non-alcoholic fatty liver disease patients with different levels of cardiovascular risk. Reports of Morphology, 23(2), 282-287. Retrieved from